RE:RE:RE:Combined ASSURE/SUSTAIN Hi GV.
I took the graph that Don presented in a webcast last fall and again down in Texas and I think at a couple of other conferences. It's all the same graph I've used.
It showed the MACE events (post hoc SUSTAIN/ASSURE) out to 210 days in the control group treated by Crestor only and the test group treated with Crestor and rvx-208. This was in the post hoc analysis of patients with diabetes mellitus and CVD. Don gave a comparison of the market size in his presentation and it is over $20 billion.
Then I fitted regression functions to the data and projected out to various time periods including 360 days for the test group. I only projected the control groups out for 45 to 60 additional days because the MACE levels were increasing exponentially and I did not feel that the projections would be reliable.
The data in the test group projected out to 12 months shows MACE levels of just above 6% vs. MACE levels of 20.6% at 210 days in the control group (treated with Crestor only).
However, in the data I sent previously you can see the projections. I really would have liked to have included the graph of the rvx-208 impact because it is dramatic and if replicated in BETonMACE it will be truly remarkable.
I am being completely subjective here but from reading about rvx-208 I'm getting the sense that it may be like an Aspirin...a very powerful health drug. I really don't know, but that is what it seems like, although, it seems more targeted i.e. diabetes mellitus with CVD but also all of the other hypertension and cardiovascular diseases and since it is an epigenetic platform the options are limitless.
Cheers
Toinv :)